Purpose:
to provide HIV-1 Env coordinates of contacts and other sites associated with neutralizing antibodies. Some of these data are also summarized in a spreadsheet (.xlsx). For details, see Help.
Download database
Env Feature ID | Title | Antibody class | Reference | Site type | Experimental method | MAb name | |
---|---|---|---|---|---|---|---|
Details | 8 | VRC01 contacts | CD4BS | Wu2011 Zhou2010 | contacts | VRC01 | |
Details | 12 | Mutation affects PGV04, b12, VRC01, CD4-IgG neutralization | CD4BS | Falkowska2012 | neutralization | neutralization assay | b12 VRC01 VRC-PG04 |
Details | 44 | VRC01 signature predictions | CD4BS | West2013 | signature | computational prediction | VRC01 |
Details | 63 | VRC01 residue prediction | CD4BS | Chuang2013 Chuang2014 | signature | VRC01 | |
Details | 73 | Sequence changes after immunotherapy with VRC01 | CD4BS | Lynch2015 | immunotherapy | sequence analysis | VRC01 |
Details | 84 | Electrostatic interactions with D368 | CD4BS | Bonsignori2016 | binding | CH235.12 CH235.9 VRC01 | |
Details | 116 | mutations affecting VRC01 binding | CD4BS | Dingens2019 Huang2016a | binding | alanine scanning, binding assay, mutational analysis | VRC01 |
Details | 123 | Mutation decreases binding to CD4BS mAbs | CD4BS | Easterhoff2017 | binding | binding assay | b12 b6 CH13 CH28 CH98 HJ16 VRC01 VRC-PG04 |
Details | 167 | Removal of glycosylation sites confers binding to germline-reverted NIH45-46 and VRC01 | CD4BS | McGuire2013 McGuire2016 | binding | VRC01 | |
Details | 200 | hypervariable loop characteristic correlations with bNAb sensitivity | CD4BS | Bricault2019 | signature | computational prediction | 12A12 3BNC117 8ANC131 CH103 CH235.12 N6 NIH45-46 VRC01 VRC07 VRC07-523-LS |
Details | 209 | Signature Analysis Summary | CD4BS | Bricault2019 | signature | computational prediction | VRC01 |
Details | 246 | Neutralization of Env 426c and its glycan-deleted mutant by CD4BS Abs | CD4BS | LaBranche2018 | neutralization | neutralization assay | 12A12 3BNC117 VRC01 VRC03 VRC07 VRC18b VRC-PG20 |
Details | 282 | Mutation affects VRC01 neutralization | CD4BS | Dingens2019 Kong2016a Schommers2020 | neutralization | neutralization assay | VRC01 |
Details | 294 | Mutations associated with immunotherapy with BG24 or VRC01 | CD4BS | Barnes2022 | immunotherapy | sequence analysis | BG24 VRC01 |
Details | 295 | Mutation abrogates BG24 OR VRC01 neutralization | CD4BS | Barnes2022 | neutralization | neutralization assay | BG24 VRC01 |
Details | 336 | VRC01 contacts | CD4BS | Dingens2019 | contacts | molecular modeling | VRC01 |
Details | 396 | mutations affecting VRC01 binding | CD4BS | Kwon2015 | binding | binding assay, mutational analysis | VRC01 |
Details | 475 | Mutation affects neutralization of VRC01 | CD4BS | ORourke2012 | neutralization | neutralization assay | VRC01 |
Details | 489 | Disulfide bond introduced in V1V2 affects binding of VRC01 | CD4BS | deTaeye2019 | binding | binding assay, mutational analysis | VRC01 |